argenx buys Forte Biosciences for $2.2B to expand immunology pipeline
What's the deal? argenx (Euronext & Nasdaq: ARGX) will acquire Forte BiosciencesDealroom has a profile for this one. Try Dealroom → (Nasdaq: FBRX) for $77 per share in cash, a total equity value of about $2.2 billion. The deal gives argenx FB102, a first-in-class anti-CD122 antibody, and builds on argenx's prior strategic investment in Forte.
Who's who? argenx, based in Amsterdam, is a global immunology company. Forte Biosciences, based in Dallas, developed FB102, its lead program, which targets pathogenic T-cell and NK-cell activity through CD122 biology.
What's the endgame? FB102 has clinical proof-of-concept in vitiligo and celiac disease from Phase 1b studies, with potential across multiple autoimmune diseases. argenx frames the antibody as a "pipeline-in-a-product" targeting conditions that have lacked innovation for decades.
Why now? The purchase advances argenx's "Vision 2030" strategy. "The acquisition of Forte Biosciences builds on the strength of that foundation and advances our ambition to be the leading immunology innovator of the future," said Karen Massey, chief executive officer of argenx.
What Forte says: "We firmly believe that argenx is the ideal strategic partner to unlock the full potential of this novel anti-CD122 antibody across a broad range of autoimmune diseases," said Paul A. Wagner, chief executive officer and chairperson of Forte Biosciences.
The signal: The all-cash deal shows large immunology players are willing to pay a premium for early clinical assets that validate novel biology. For argenx, adding a differentiated mechanism early in development is a bet on long-term portfolio growth rather than near-term revenue.
Read more: fortebiorx.com
Image credit: Generated with Gemini
